|
|
Article: SciClone Gets $10.6M 'Insurance' Financing To Advance Zadaxin.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
With more than $10 million in hand from a direct offering priced earlier this month, SciClone Pharmaceuticals Inc. is forging ahead with Phase III hepatitis C trials in the U.S. and Phase III hepatitis B trials in Japan for the immune-system booster Zadaxin thymosin alpha 1 (thymalfasin).
The direct offering to institutional investors, for which A.G. Edwards & Sons in St. Louis acted as placement agent, was filed in November of last year and declared effective in May. About 4.08 million shares of SciClone common stock were priced at $2.60 per share, raising about $10.62 million.
San Mateo, Calif.-based SciClone already had ...